Meeting
2024 ASCO Annual Meeting
7+3 versus decitabine + venetoclax: A global, propensity-matched study comparing outcomes for both regimens in AML.
Authors
Varada Salimath
Baylor University Medical Center, Dallas, TX
Varada Salimath , James David Mackey , Brittany Miles , Ankit Mehta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6537)
DOI
10.1200/JCO.2024.42.16_suppl.6537
Abstract #
6537
Poster Bd #
96
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
First Author: James K. McCloskey
Poster
2022 ASCO Annual Meeting
Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.
First Author: Geoffrey L. Uy
Poster
2020 ASCO Virtual Scientific Program
Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.
First Author: Brian Andrew Jonas
Poster
2020 ASCO Virtual Scientific Program
Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).
First Author: Tapan M. Kadia